stockrow
Friday 6 November 2026
Export MBX’s income statement to Excel — free account
MBX Biosciences, Inc.
- EPS
- −34.5%
- Free cash flow
- −29.7%
Quarter to June 2026, against a year earlier
51.27
2.81
+5.80%
Follow MBX
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
32.95 | 24.62 | 30.79 | 18.08 |
Net Debt/EBITDA |
16.40 | 14.52 | 16.18 | 10.25 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.00 | 0.83 | 0.86 | 0.61 | |
Capex/Depreciation |
(7.98) | (13.22) | (6.83) | (11.41) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.64) | (0.52) | (0.44) | (0.49) | |
Cash per Share |
11.45 | 10.24 | 9.45 | 8.78 | |
Shareholders Equity per Share |
11.33 | 10.11 | 9.40 | 8.59 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.33 | 10.11 | 9.40 | 8.59 | |
Free Cash Flow |
(21.93) | (19.09) | (20.64) | (23.52) | |
Working Capital |
385.44 | 366.04 | 433.97 | 404.20 | |
Capital Expenditures |
(0.40) | (0.79) | (0.44) | (0.90) | |
Net Current Asset Value |
384.96 | 365.62 | 433.59 | 401.49 | |
| Other line items | |||||
Quick Ratio |
32.47 | 24.12 | 30.20 | 17.69 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.63) | (0.50) | (0.43) | (0.47) | |
Capex per Share |
(0.01) | (0.02) | (0.01) | (0.02) | |
Average Payables |
4.39 | 4.16 | 5.61 | 5.06 | |
Average Assets |
341.24 | 326.84 | 349.31 | 333.72 | |
Average Common Equity |
329.45 | 313.33 | 336.59 | 314.39 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates